ERBB2 and breast carcinoma: Due to its efficacy in the phase I TROPION-PanTumor01 trial in HER2-negative breast cancer,84 it is currently being studied in patients with advanced breast cancer via the phase III TROPION-Breast 01 [NCT05104866] and the TROPION-Breast 02 study [NCT05374512].